Exelixis (EXEL) Cash from Investing Activities (2010 - 2026)
Exelixis' (EXEL) quarterly Cash from Investing Activities came in at -$51.1 million in Q2 2026, down 202.62% year-on-year from $49.8 million in Q2 2025, and down 287.47% quarter-over-quarter from $27.2 million in Q1 2026.
Exelixis (EXEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$51.1 million for Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 202.62% year-over-year to -$51.1 million in Q2 2026; TTM through Apr 2026 was $249.6 million, a 239.59% increase from a year earlier, with the FY2026 full-year figure at $350.4 million, up 400.08% from the prior year.
- Cash from Investing Activities slipped to -$51.1 million in Q2 2026 per EXEL's latest filing, from $27.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $248.0 million in Q3 2025 and bottomed at -$245.8 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$49.6 million (2023), against an average of -$21.7 million.
- Across the five-year window, Cash from Investing Activities tumbled 1782.67% in 2022 and soared 325.43% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$245.8 million in 2022, then surged by 125.12% to $61.7 million in 2023, then sank by 451.73% to -$217.1 million in 2024, then jumped by 111.7% to $25.4 million in 2025, then sank by 301.02% to -$51.1 million in 2026.
- Per Business Quant, the three latest EXEL Cash from Investing Activities figures stand at -$51.1 million (Q2 2026), $27.2 million (Q1 2026), and $25.4 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | -51.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -51.07 Mn |
| Apr 3, 2026 | -51.07 Mn |
| Jan 2, 2026 | 27.24 Mn |
| Jan 2, 2026 | 27.24 Mn |
| Oct 3, 2025 | 25.41 Mn |
| Oct 3, 2025 | 25.41 Mn |
| Jul 4, 2025 | 248.03 Mn |
| Jul 4, 2025 | 248.03 Mn |
| Apr 4, 2025 | 49.76 Mn |
| Apr 4, 2025 | 49.76 Mn |
| Jan 3, 2025 | -93.20 Mn |
| Jan 3, 2025 | -93.20 Mn |
| Sep 27, 2024 | -217.15 Mn |
| Sep 27, 2024 | -217.15 Mn |
| Jun 28, 2024 | 81.77 Mn |
| Jun 28, 2024 | 81.77 Mn |
| Mar 29, 2024 | 111.79 Mn |
| Mar 29, 2024 | 111.79 Mn |
| Dec 29, 2023 | 61.74 Mn |
| Dec 29, 2023 | 61.74 Mn |